(Q37133284)

18 August 2017

1 reference

title

Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence (English)

1 reference

18 August 2017

Alessandro Serretti

2

0 references

author name string

Chi-Un Pae

series ordinal

1

1 reference

18 August 2017

Ashwin A Patkar

series ordinal

3

1 reference

18 August 2017

Praksh S Masand

series ordinal

4

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

367-388

1 reference

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

Atypicality of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

Aripiprazole augmentation in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

The Yale-Brown Obsessive Compulsive Scale. II. Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822050-00002

Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions

21 January 2018

1 reference

12 December 2020

Kynurenine pathway in major depression: Evidence of impaired neuroprotection

1 reference

12 December 2020

5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential

1 reference

12 December 2020

Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons

1 reference

12 December 2020

Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms

1 reference

12 December 2020

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability

1 reference

12 December 2020

Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial

1 reference

12 December 2020

Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls

1 reference

12 December 2020

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

12 December 2020

Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia

1 reference

12 December 2020

5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats

1 reference

12 December 2020

5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.

1 reference

12 December 2020

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

1 reference

12 December 2020

Pindolol augmentation of antidepressant response

1 reference

12 December 2020

Depressive mania associated with nonresponse to antimanic agents

1 reference

12 December 2020

Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims

1 reference

12 December 2020

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers

1 reference

12 December 2020

Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

1 reference

12 December 2020

The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

1 reference

12 December 2020

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

12 December 2020

Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems

1 reference

12 December 2020

Aripiprazole-related tardive dyskinesia

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

1 reference

12 December 2020

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features

1 reference

12 December 2020

Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes

1 reference

12 December 2020

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review

1 reference

12 December 2020

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

1 reference

12 December 2020

A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.

1 reference

12 December 2020

Serotonin Syndrome During Treatment With Paroxetine and Risperidone

1 reference

12 December 2020

Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation

1 reference

12 December 2020

Dopamine partial agonists: a new class of antipsychotic

1 reference

12 December 2020

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Dopaminergic mechanism of antidepressant action in depressed patients

1 reference

12 December 2020

Aripiprazole: new drug. Just another neuroleptic

1 reference

12 December 2020

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

1 reference

12 December 2020

Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors

1 reference

12 December 2020

The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine

1 reference

12 December 2020

Azapirones for generalized anxiety disorder

1 reference

12 December 2020

Focus on aripiprazole

1 reference

12 December 2020

Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions

1 reference

12 December 2020

The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.

1 reference

12 December 2020

The hospital anxiety and depression scale

1 reference

12 December 2020

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

12 December 2020

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors

1 reference

12 December 2020

Atypical antipsychotics in bipolar depression: potential mechanisms of action.

1 reference

12 December 2020

The biology of serotonin receptors: focus on migraine pathophysiology and treatment

1 reference

12 December 2020

Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.

1 reference

12 December 2020

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

12 December 2020

A double-blind, placebo-controlled study of memantine in the treatment of major depression

1 reference

12 December 2020

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

12 December 2020

Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine

1 reference

12 December 2020

Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex

1 reference

12 December 2020

Dose-dependent augmentation effect of bromocriptine in a case with refractory depression

1 reference

12 December 2020

Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine

1 reference

12 December 2020

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

1 reference

12 December 2020

Antidepressant effects of ketamine in depressed patients

1 reference

12 December 2020

5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives

1 reference

12 December 2020

Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Treatment-resistant anxiety disorders

1 reference

12 December 2020

Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders

1 reference

12 December 2020

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

12 December 2020

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies

1 reference

12 December 2020

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

1 reference

12 December 2020

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Adjunctive aripiprazole in treatment-resistant bipolar depression.

1 reference

12 December 2020

Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

1 reference

12 December 2020

Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

1 reference

12 December 2020

Gepirone in the treatment of major depression

1 reference

12 December 2020

5-HT6 receptors: a novel target for cognitive enhancement

1 reference

12 December 2020

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

12 December 2020

The impact of treatment-resistant depression on health care utilization and costs

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)

1 reference

12 December 2020

The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex

1 reference

12 December 2020

Bipolar depression: the role of atypical antipsychotics

1 reference

12 December 2020

Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands

1 reference

12 December 2020

Serotonin in migraine: theories, animal models and emerging therapies.

1 reference

12 December 2020

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

12 December 2020

The many faces of fatigue in major depressive disorder

1 reference

12 December 2020

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

12 December 2020

Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?

1 reference

12 December 2020

A novel augmentation strategy for treating resistant major depression

1 reference

12 December 2020

Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex

1 reference

12 December 2020

Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity

1 reference

12 December 2020

Reevaluating therapies for bipolar depression.

1 reference

12 December 2020

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020

Serotonin syndrome and atypical antipsychotics

1 reference

12 December 2020

The mesolimbic dopamine system as a target for rapid antidepressant action.

1 reference

12 December 2020

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

1 reference

12 December 2020

Aripiprazole for schizophrenia

1 reference

12 December 2020

Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine

1 reference

12 December 2020

Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet Study

1 reference

12 December 2020

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

12 December 2020

Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naive patient

1 reference

12 December 2020

Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia

1 reference

12 December 2020

Aripiprazole augmentation for treatment of patients with inadequate antidepressants response

1 reference

12 December 2020

Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia

1 reference

12 December 2020

Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex

1 reference

12 December 2020

Olanzapine/fluoxetine combination for bipolar depression

1 reference

12 December 2020

Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder

1 reference

12 December 2020

The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder

1 reference

12 December 2020

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

1 reference

12 December 2020

10.2165/00023210-200822050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

1025335317

0 references

1 reference